Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06633497 · ClinicalTrials.gov registry record

Evaluating the Role of the Microbiome in Antidepressant Treatment in Adolescents.

A clinical trial, sponsored by University of California, San Diego.

Not yet
Registry status
100
Enrollment target

NCT06633497 is a clinical trial that has not yet begun recruiting, run by University of California, San Diego. The registered enrollment target is 100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06633497 has not yet begun recruiting, sponsored by University of California, San Diego.

NOT YET RECRUITING
Registry status
100 participants
Enrollment target

Study Summary

The goal of this observational study is to learn about the role of the human gut microbiome in antidepressant treatment response in adolescents with Major Depressive Disorder (MDD). Specifically, the study aims to collect microbiota samples of adolescents treated with fluoxetine, over the span of 8-weeks, to: * determine the influence of the microbiome on the efficacy of fluoxetine to treat adolescent depression. * test whether the gut microbiome from different timepoints can predict ultimate success of fluoxetine * investigate the interaction of gut microbiome composition and pharmacogenetic metabolizer status on steady-state plasma concentrations of fluoxetine. Depression symptom severity will be evaluated upon enrollment and 6-weeks into antidepressant treatment.

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-11
Est. Completion 2026-10

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT06633497

The ClinicalTrials.gov registry entry for NCT06633497 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT06633497 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06633497 about?

NCT06633497 is a clinical study titled "Evaluating the Role of the Microbiome in Antidepressant Treatment in Adolescents.". The goal of this observational study is to learn about the role of the human gut microbiome in antidepressant treatment response in adolescents with Major Depressive Disorder (MDD). Specifically, the study aims to collect microbiota samples of adolescents treated with fluoxetine, over the span of 8-...

What is the current status of trial NCT06633497?

This trial is currently not yet recruiting. The enrollment target is 100 participants. The study started on 2024-11. Estimated completion is 2026-10.

Who is sponsoring clinical trial NCT06633497?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.